Document:

<PAGE>

                 AMERICAN EQUITY INVESTMENT LIFE HOLDING COMPANY
                         2000 DIRECTOR STOCK OPTION PLAN

         WHEREAS, the Board of Directors of American Equity Investment Life
Holding Company (the "Company") deem it in the best interest of the Company
that persons who serve on the Board of Directors of the Company but who are
not employees of the Company be given an opportunity to acquire an interest
in the operation and growth of the Company as a means of assuring their
maximum effort and continued association with the Company; and

         WHEREAS, the Board has determined to grant certain directors of the
Company compensation in the form of non-qualified stock options pursuant to
this Plan;

         NOW, THEREFORE, the Board does hereby adopt this 2000 Director Stock
Option Plan, subject to approval, within twelve (12) months of the date of
adoption, by at least a majority of the shares voting at a stockholder's
meeting, and subject to any necessary authorizations from any governmental
authority.

                                    ARTICLE I
                                  DEFINITIONS

         Except where the context otherwise indicates, the following definitions
apply:

         1.1 " Affiliate" means parent or subsidiary corporations of the
Company, as defined in Sections 424(e) and (f) of the Code (but substituting the
Company for employer corporation), including parents or subsidiaries of the
Company which become such after adoption of the Plan.

         1.2 "Agreement" means a written agreement granting an Option that is
executed by the Company and the Optionee.

         1.3 "Board" means the Board of Directors of the Company.

         1.4 "Code" means the Internal Revenue Code of 1986, as amended.

         1.5 " Committee" means the Board.

         1.6 "Common Stock" means the Common Stock, par value $1.00 per share,
of the Company.

         1.7 "Company" means American Equity Investment Life Holding Company, an
Iowa corporation.

         1.8 "Date of Exercise" means the date on which the Company receives
notice of the exercise of an Option and payment of the exercise price in
accordance with the terms of Article VII.

         1.9 "Date of Grant" means the date on which an Option is granted under
the Plan.

         1.10 "Director" means a member of the Board of Directors of the
Company.

         1.11 "Disability" means permanent and total disability within the
meaning of Section 22(e)(3) of the Code, as determined by the Committee.

<PAGE>

         1.12 "Eligible Individual means any Director of the Company who is
not also an Employee and has not been an Employee at any time during the
two-year period preceding the date on which an Option is granted to such
Director.

         1.13 "Employee" means any employee of the Company or an Affiliate or
any person who has been hired to be an employee of the Company or an
Affiliate.

         1.14 "Fair Market Value" means the fair market value of a Share as
determined by the Committee pursuant to a reasonable method adopted in good
faith for such purpose.

         1.15 "Non-qualified Stock Option" means an Option granted under the
Plan that does not qualify as an incentive stock option under Section 422 of
the Code.

         1.16 "Option" means an option to purchase Shares granted under the
Plan.

         1.17 "Option Period" means the period during which an Option may be
exercised.

         1.18 "Option Price" means the price per Share at which an Option may
be exercised; provided, however, the Option Price shall be not less than the
Fair Market Value of a Share as of the Date of Grant. The Option Price of any
Option shall be subject to adjustment to the extent provided in Article IX
hereof, subject to Section 6.3 hereof.

         1.19 "Optionee" means an Eligible Individual to whom an Option has
been granted.

         1.20 "Plan" means the American Equity Investment Life Holding
Company 2000 Director Stock Option Plan.

         1.21 "Share" means a share of Common Stock.

                                   ARTICLE II
                                    PURPOSE

         The Plan is intended to assist the Company in attracting and
retaining Eligible Individuals of outstanding ability and to promote the
identification of their interests with those of the stockholders of the
Company.

                                   ARTICLE III
                                 ADMINISTRATION

         The Committee shall administer the Plan and shall have plenary
authority and discretion, subject to the provisions of the Plan, to determine
the terms (which terms need not be identical) of all Options including, but
not limited to, which Eligible Individuals shall be granted Options, the time
or times at which Options are granted, the Option Price, the number of Shares
subject to an Option, any provisions relating to vesting, any circumstances
in which Options terminate or Shares may be repurchased by the Company, the
period during which Options may be exercised and other restrictions on
Options. Subject to the provisions of the Plan, the Committee shall have
plenary authority to construe and interpret the Plan and the Agreements, to
prescribe, amend and rescind rules and regulations relating to the Plan and
to make all other determinations deemed necessary or advisable for the
administration of the Plan, including, but not limited to, any determination
to accelerate the vesting of outstanding Options. The determinations of the
Committee on the matters referred to in this Article III shall be binding and
final.

<PAGE>

                                   ARTICLE IV
                                  ELIGIBILITY

         Options may be granted only to Eligible Individuals.

                                    ARTICLE V
                           STOCK SUBJECT TO THE PLAN.

         5.1 NUMBER OF SHARES RESERVED. Subject to adjustment provided in
Article IX hereof, the maximum number of Shares that may be issued under the
Plan is 75,000 Shares (to be adjusted to 225,000 shares if the Board
authorizes a three-for-one stock split at its May 5, 2000 meeting).

         5.2 TERMINATED OPTIONS AVAILABLE FOR GRANT. If an Option expires or
terminates for any reason without having been fully exercised, the unissued
Shares which had been subject to such Option shall become available for the
grant of additional Options.

                                   ARTICLE VI
                                     OPTIONS

         6.1 NON-QUALIFIED STOCK OPTIONS. All Options granted under the Plan
shall be Non-qualified Stock Options. Each Option granted under the Plan
shall be evidenced by an Agreement that specifies the terms and conditions of
the grant. Options granted to Eligible Individuals shall be subject to the
terms and conditions set forth in this Article VI hereof and such other terms
and conditions not inconsistent with the Plan as the Committee may specify.

         6.2 OPTION PERIOD. The Option Period for Options granted to Eligible
Individuals shall be determined by the Committee and specifically set forth
in the Agreement; provided, however, that (a) an Option shall not be
exercisable after ten years from its Date of Grant; and (b) in the case of
the termination as Director of an Optionee, or the death or disability of an
Optionee, the Option Period shall be as follows:

         a.       TERMINATION AS DIRECTOR. Upon termination of an Optionee's
                  service as a Director of the Company, his or her Option
                  privileges, shall be limited to the shares purchasable by him
                  or her as of the date that his or her directorship was
                  terminated, and such Option privileges shall expire sixty (60)
                  days from the date that his or her directorship was
                  terminated. Nothing contained herein shall be construed to
                  extend the ultimate term of the Option beyond the period of
                  time as set out above.

         b.       DISABILITY OR DEATH OF OPTIONEE. If an Optionee's directorship
                  is terminated because of his death or disability, his Option
                  privileges shall expire unless exercised within one (1) year
                  after the date that his directorship was terminated. In the
                  event of the death of the Optionee, his Options may be
                  exercised by the Optionee's designated beneficiary. Nothing
                  contained herein shall be construed to extend the ultimate
                  term of the Option beyond the period of time as set out above.

         6.3 NO REISSUANCE AT REDUCED PRICE. Notwithstanding anything to the
contrary in this Plan, without the approval of the stockholders of the
Company, no Option shall be issued in exchange for or as a reissuance of any
outstanding Option or the Option Price for any

<PAGE>

outstanding Option shall not be changed, if the effect of such exchange or
change would be to reduce the Option Price for any outstanding Option, except
as necessary to reflect the effect of a stock split, stock dividend or
similar event as described in Article IX hereof.

         6.4 MAXIMUM OPTIONS PER DIRECTOR. The maximum number of Options
which may be granted to any Eligible Individual in any one fiscal year is
3,500 (subject to adjustment to reflect the effect of a stock split, stock
dividend or similar event, as described in Article IX hereof).

                                   ARTICLE VII
                               EXERCISE OF OPTIONS

         7.1 NOTICE OF EXERCISE. An Option may, subject to the terms of the
applicable Agreement under which it is granted, be exercised in whole or in
part by the delivery to the Company of written notice of the exercise, in
such form as the Committee may prescribe, accompanied by full payment of the
Option Price for the Shares with respect to which the Option is exercised as
provided in Section 7.2 hereof.

         7.2 PAYMENT OF EXERCISE PRICE Payment of the aggregate Option Price
for the Shares with respect to which an Option is being exercised shall be
made in cash; provided however, that the Committee, in its sole discretion,
may provide in an Agreement that part or all of such payment may be made by
the Optionee in one or more of the following manners:

         (i)      By delivery (including constructive delivery) to the Company
                  of Shares valued at Fair Market Value on Date of Exercise; or

         (ii)     By delivery on a form prescribed by the Committee of a
                  properly executed exercise notice and irrevocable instructions
                  to a registered securities broker approved by the Committee to
                  sell Shares and promptly deliver cash to the Company.

         7.3 MINIMUM EXERCISE. No Option may be exercised for less than
fifty(50) shares.

         7.4 MINIMUM VESTING PERIOD. In the absence of a specified vesting
schedule established by the Committee and set forth in the applicable
agreement evidencing the grant of any options, all options will vest six
months after the date of grant. Should the directorship of any Optionee be
terminated for any reason (except death or disability) with or without cause,
prior to the expiration of six months or the vesting schedule established by
the Committee, which ever is the later, the Optionee will forfeit all options
not fully vested on the effective date of such termination.

         7.5 MINIMUM VESTING PERIOD. In the absence of a specified vesting
schedule established by the Committee and set forth in the applicable
agreement evidencing the grant of any options, all options will vest one year
after the date of grant. Should the Optionee cease to serve as a Director of
the Company for any reason (except death or disability) with or without
cause, prior to the expiration of one year or the vesting schedule
established by the Committee, which ever is the later, the Optionee will
forfeit all options not fully vested on the effective date of such
termination.

         7.5 ACCELERATION OF VESTING. If an Option contains a vesting
schedule or has not become totally exercisable as of the date of any of the
following events, such vesting schedule may be accelerated, and/or any other
restrictions to exercise may be removed upon delivery to the Committee of a
written election of such acceleration by the Optionee (or the designated
beneficiary of a deceased Optionee):

                  (i)      The death of the Optionee;

                  (ii)     The Disability of the Optionee;

<PAGE>

                  (iii)    A "change of control" as hereinafter defined.

         7.6 CHANGE OF CONTROL. For purposes of this Plan, a "change in
control" shall be deemed to have occurred on such date if:

         (i)      Any person, organization or association of persons or
                  organizations acting in concert, excluding Affiliates of the
                  Company itself, shall acquire more than twenty percent (20%)
                  of the outstanding voting stock of the Company in whole or in
                  part by means of an offer made publicly to the holders of all
                  or substantially all of the outstanding shares of any one or
                  more classes of the voting securities of the Company to
                  acquire such shares for cash, other property or a combination
                  thereof; or

         (ii)     Any person, organization or association of persons or
                  organizations acting in concert shall succeed in electing two
                  or more directors in any one election in opposition to those
                  proposed by management; or

         (iii)    The Company transfers all or substantially all of its
                  operating properties and assets to another person,
                  organization or association of persons or
                  organizations, excluding affiliates of the Company
                  itself; or

         (iv)     The Company shall consolidate with or merge into any person,
                  firm or corporation unless the Company or Affiliate shall be
                  the continuing corporation or the successor corporation;

                                  ARTICLE VIII
                            RESTRICTIONS ON TRANSFER

         Options shall not be transferable other than by will or the laws of
descent and distribution. An Option may be exercised during the Optionee's
lifetime only by the Optionee or, in the event of his or her legal
disability, by his or her legal representative. The Shares acquired pursuant
to the Plan shall be subject to such restrictions and agreements regarding
sale, assignment, encumbrances, or other transfers or dispositions thereof
(i) as are in effect among the stockholders of the Company at the time such
Shares are acquired or (ii) as the Committee shall deem appropriate or as are
required by applicable law.

                                   ARTICLE IX
                               CAPITAL ADJUSTMENTS

         In the event of any change in the outstanding Common Stock by reason
of any stock dividend, split-up (or reverse stock split), recapitalization,
reclassification, reorganization, reincorporation, combination or exchange of
shares, merger, consolidation, liquidation or similar change in corporate
structure, the Committee may, in its discretion and to the extent necessary
to compensate for the effect thereof, provide for a substitution for or
adjustment in (i) the number and class of Shares subject to outstanding
Options, (ii) the Option Price of outstanding Options, and (iii) the
aggregate number and class of Shares that may be issued under the Plan.

<PAGE>

                                    ARTICLE X
                            TERMINATION OR AMENDMENT

         The Board may amend, alter, suspend or terminate the Plan in any
respect at any time; provided, however, that after the Plan has been approved
by the stockholders of the Company, no amendment, alteration, suspension or
termination of the Plan shall be made by the Board without approval of (i)
the Company's stockholders to the extent stockholder approval is required by
applicable law or regulations and (ii) each affected Optionee if such
amendment, alteration, suspension or termination would adversely affect his
or her rights or obligations under any Option granted prior to the date of
such amendment, alteration, suspension or termination. No Option may be
granted nor any Shares issued under the Plan during any suspension or after
termination of the Plan.

                                   ARTICLE XI
       MODIFICATION, EXTENSION AND RENEWAL OF OPTIONS; SUBSTITUTED OPTIONS

         Subject to the terms and conditions of the Plan, the Committee may
modify, extend or renew the terms of any outstanding Options, or accept the
surrender of outstanding Options granted under the Plan or options and stock
appreciation rights granted under any other plan of the Company or an
Affiliate (to the extent not theretofore exercised) and authorize the
granting of new Options in substitution therefor (to the extent not
theretofore exercised). Subject to Section 6.3 hereof, any such substituted
Options may specify a longer term than the surrendered options and stock
appreciation rights, or have any other provisions that are authorized by the
Plan. Notwithstanding the foregoing, however, no modification of an Option
shall, without the consent of the Optionee, alter or impair any of the
Optionee's rights or obligations under such Option.

                                   ARTICLE XII
                            EFFECTIVENESS OF THE PLAN

         The Plan and any amendment thereto shall be effective on the date on
which it is adopted by the Board, provided that any such adoption requiring
stockholder approval is subject to approval by vote of the stockholders of
the Company within 12 months after such adoption by the Board.

                                  ARTICLE XIII
                                   WITHHOLDING

         The Company's obligation to deliver Shares or pay any amount
pursuant to the terms of any Option shall be subject to the satisfaction of
applicable federal, state and local tax withholding requirements. To the
extent provided in the applicable Agreement and in accordance with rules
prescribed by the Committee, an Optionee may satisfy any such withholding tax
obligation by any of the following means or by a combination of such means:
(i) tendering a cash payment, (ii) authorizing the Company to withhold Shares
otherwise issuable to the Optionee, or (iii) delivering to the Company
already owned and unencumbered Shares.

                                   ARTICLE XIV
                                TERM OF THE PLAN

         Unless sooner terminated by the Board pursuant to Article X hereof,
the Plan shall terminate on June 30, 2010, and no Options may be granted
after such date. The termination of the Plan shall not affect the validity of
any Option outstanding on the date of termination.

<PAGE>

                                   ARTICLE XV
                          INDEMNIFICATION OF COMMITTEE

         In addition to such other rights of indemnification as they may have
as Directors or as members of the Committee, the members of the Committee
shall be indemnified by the Company against the reasonable expenses,
including attorneys' fees, actually and reasonably incurred in connection
with the defense of any action, suit or proceeding, or in connection with any
appeal therein, to which they or any of them may be a party by reason of any
action taken or failure to act under or in connection with the Plan or any
Option granted hereunder, and against all amounts reasonably paid by them in
settlement thereof or paid by them in satisfaction of a judgment in any such
action, suit or proceeding, if such members acted in good faith and in a
manner which they believed to be in, and not opposed to, the best interests
of the Company.

                                   ARTICLE XVI
                               GENERAL PROVISIONS

         16.1 NO OTHER RIGHTS CONFERRED. The establishment of the Plan shall
not confer upon any Eligible Individual any legal or equitable right against
the Company, any Affiliate or the Committee, except as expressly provided in
the Plan.

         16.2 NO CONTRACT RIGHTS. The Plan does not constitute inducement or
consideration for the service of any Eligible Individual, nor is it a
contract between the Company or any Affiliate and any Eligible Individual.
Participation in the Plan shall not give an Eligible Individual any right to
be retained in the service of the Company.

         16.3 NO LIMITATION ON OTHER STOCK OPTION, ETC. Neither the adoption
of this Plan nor its submission to the stockholders, shall be taken to impose
any limitations on the powers of the Company or its Affiliates to issue,
grant or assume options, warrants, rights, or restricted stock, otherwise
than under this Plan, or to adopt other stock option or restricted stock
plans or to impose any requirement of stockholder approval of the same.

         16.4 PLAN INTEREST NOT SUBJECT TO CREDITOR CLAIMS. The interests of
any Eligible Individual under the Plan are not subject to the claims of
creditors and may not, in any way, be assigned, alienated or encumbered
except as provided in an Agreement.

         16.5 APPLICABLE LAW. The Plan shall be governed, construed and
administered in accordance with the laws of the State of Iowa.

         16.6 REPRESENTATIONS REGARDING INVESTMENT INTENT; RESTRICTIVE
LEGENDS. The Committee may require each person acquiring Shares pursuant to
Options hereunder to represent to and agree with the Company in writing that
such person is acquiring the Shares without a view to distribution thereof.
The certificates for such Shares may include any legend which the Committee
deems appropriate to reflect any restrictions on transfer. All certificates
for Shares issued pursuant to the Plan shall be subject to such stock
transfer orders and other restrictions as the Committee may deem advisable
under the rules, regulations and other requirements of the Securities and
Exchange Commission, any stock exchange or interdealer quotation system upon
which the Common Stock is then listed or quoted, and any applicable federal
or state securities laws. The Committee may place a legend or legends on any
such certificates to make appropriate reference to such restrictions. The
certificates for Shares acquired pursuant to an option may also include any
legend which the Committee deems appropriate to reflect restrictions
contained in this Plan or in the applicable Agreement or to comply with the
Iowa Business Corporation Act.

<PAGE>

         16.7 REGULATORY APPROVALS. The Company shall not be required to
issue any certificate or certificates for Shares upon the exercise of
Options, or record any person as a holder of record of Shares, without
obtaining, to the complete satisfaction of the Committee, the approval of all
regulatory bodies deemed necessary by the Committee, and without complying to
the Committee's complete satisfaction, with all rules and regulations, under
federal, state or local law deemed applicable by the Committee.<PAGE>

                                                                    EXHIBIT 10.1

CONFIDENTIAL TREATMENT REQUEST. CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE
BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION.

           DEVELOPMENT, MANUFACTURING AND MARKETING AGREEMENT

           THIS DEVELOPMENT, MANUFACTURING AND MARKETING AGREEMENT dated as of
June 7, 2000 (the "Agreement"), is entered into between SICOR INC., a Delaware
corporation ("Sicor"), having a place of business located at 19 Hughes, Irvine,
California 92618, and AESGEN, INC., a Delaware corporation ("Aesgen"), having a
place of business located at 2 Research Way, Third Floor East, Princeton, New
Jersey 08540.

                              W I T N E S S E T H :

           WHEREAS, Aesgen owns or has rights to certain technology which may be
used in the development of injectable * * * finished products.

           WHEREAS, Aesgen desires to have Sicor develop certain injectable * *
* finished products on the terms and subject to the conditions set forth below.

           WHEREAS, Aesgen wishes to grant Sicor, and Sicor wishes to acquire
from Aesgen, an exclusive license to manufacture, market and sell such products
on the terms and subject to the conditions set forth below.

           NOW, THEREFORE, in consideration of the foregoing premises and the
mutual covenants herein contained, the parties hereby agree as follows:

                                    ARTICLE 1

                                   DEFINITIONS

           For purposes of this Agreement, the terms defined in this Article 1
shall have the respective meanings set forth below:

           1.1 "AFFILIATE" shall mean, with respect to any Person, any other
Person which directly or indirectly controls, is controlled by, or is under
common control with, such Person. A Person shall be regarded as in control of
another Person if it owns, or directly or indirectly controls, at least fifty
percent (50%) of the voting stock or other ownership interest of the other

           ***  - Confidential treatment requested.

<PAGE>

Person, or if it directly or indirectly possesses the power to direct or cause
the direction of the management and policies of the other Person by any means
whatsoever.

           1.2 "ANDA" shall mean, with respect to a Product, the Abbreviated New
Drug Application for that Product which has been or will be submitted to the
FDA, including any amendments or supplements thereto.

           1.3 "BULK INTERMEDIATE" shall mean * * *.

           1.4 "FDA" shall mean the United States Food and Drug Administration.

           1.5 "FIFO" shall mean the first in, first out method of accounting.

           1.6 "GROSS PROFIT" shall mean, with respect to any Product in a given
period, the Net Sales of such Product in such period less the Manufacturing Cost
of such Product in such period, but in no event shall "Gross Profit" be less
than zero.

           1.7 "KNOW-HOW" shall mean all information and data, which is not
generally known, including formulae, procedures, protocols, techniques and
results of experimentation and testing, which are necessary or useful to make,
use, develop, sell or seek regulatory approval in any country to market the
Products, which Aesgen owns or controls and which is in the possession of Aesgen
on the date of this Agreement or thereafter during the term of this Agreement.

           1.8 "LIQUID PRODUCT" shall mean one of the Products that are in a
liquid presentation.

           1.9 "LYOPHILIZED PRODUCT" shall mean one of the Products that are in
a lyophilized presentation.

                     1.9.1 "* * * LYOPHILIZED PRODUCT" shall mean the * * * vial
presentation of the Lyophilized Product.

                     1.9.2 "* * * LYOPHILIZED PRODUCT" shall mean the * * * vial
presentation of the Lyophilized Product.

           1.10 "MANUFACTURING COST" shall mean (a) with respect to any Product
manufactured in finished dosage form and packaged by a Third Party Manufacturer,
the invoice amount to be paid to such Third Party Manufacturer for such Product,
or (b) with respect to any Product manufactured or packaged by Sicor, the
fully-burdened cost of manufacturing the finished dosage form of any particular
formulation of such Product, together with the packaging thereof, including the
Cost of Bulk Intermediate, Materials, Direct Labor and Benefits, and Overhead,
with inventory used for such Product shipped to be determined on a FIFO basis
but consistent with Product lot releases, all as determined in accordance with
generally accepted accounting

           ***  - Confidential treatment requested.

                                    -2-

<PAGE>

principles and consistently with the manufacturer's accounting practices for
other products manufactured.

                     1.10.1 "MATERIALS" shall mean, (a) with respect to a
Product, those items which form an integral and direct part of the finished
dosage form of the particular Product, other than Bulk Intermediate and (b) with
respect to Bulk Intermediate, those items which form an integral and direct part
of the finished form of the Bulk Intermediate; and; in each case, are necessary
for the production of a Product or the Bulk Intermediate, as applicable,
including cartons, labels, package inserts and shippers.

                     1.10.2 "DIRECT LABOR AND BENEFITS" shall mean, with respect
to a Product or Bulk Intermediate, that portion of basic wages, labor and
related payroll taxes and employee benefits spent in actual production of the
particular Product or Bulk Intermediate which can be identified with or charged
to such particular Product or Bulk Intermediate.

                      1.10.3 "OVERHEAD" shall mean all operating expenses
incurred by and in support of the particular manufacturing cost centers,
purchasing department and quality assurance operations, with respect to such
Product or Bulk Intermediate, including the following:

                      -     Indirect labor, related payroll taxes and
                            employee benefits

                      -     Depreciation

                      -     Taxes

                      -     Insurance

                      -     Rent

                      -     Repairs and maintenance

                      -     Supplies

                      -     Utilities

                      -     Factory administrative expenses

                      Notwithstanding the foregoing, for the purpose of
calculating Gross Profit pursuant to Sections 1.6, 6.1 and 6.2 hereof, Overhead
shall exclude costs solely attributable to gross inefficiencies relating to
Sicor's or Sicor S.p.A.'s manufacturing of other products, as applicable.

                      1.10.4 "COST OF BULK INTERMEDIATE" shall mean the
fully-burdened cost of Sicor S.p.A. in manufacturing the Bulk Intermediate,
including Materials, Direct Labor and Benefits, and Overhead of Sicor S.p.A.,
plus any amounts payable to VinChem Inc. in connection with the purchase and
supply of Bulk Intermediate up to a maximum amount of * * * of Net Sales.

           ***  - Confidential treatment requested.

                                    -3-

<PAGE>

           1.11      "NET SALES" shall mean:

                     1.11.1 with respect to any Product sold by Sicor or its
Affiliates, the invoiced sales price of such Product billed to Sicor's customers
(other than Third Party Marketers), less (a) credits, allowances, discounts and
rebates to, group buying fees and chargebacks from the account of, such
independent customers for spoiled, damaged, out-dated, recalled and returned
Product; (b) actual freight and insurance costs incurred in transporting such
Product in final form to such customers; (c) trade discounts, cash discounts,
quantity discounts, rebates and other price reduction programs directly
attributable to the sale of such Product; (d) sales, value-added and other
direct taxes incurred; and (e) customs duties, surcharges and other governmental
charges incurred in connection with the exportation or importation of such
Product in final form; or

                     1.11.2 with respect to any Product sold by any Third Party
Marketer, (a) the "net sales" of such Product sold by a Third Party Marketer to
its customers, as determined in the agreement between Sicor and such Third Party
Marketer, plus (b) any compensation of any kind, whether in cash or in other
goods or services, as and when received from such Third Party Marketer for the
right to sell and market the Products (including amounts received prior to
Product launch), reduced by (c) any compensation as and when paid to such Third
Party for the right to market and sell such Product on behalf of Sicor
(including prior to Product launch); provided, however, that such compensation
shall not exceed * * * of the "net sales" of such Product; and further reduced
(d) in the event that any portion of the compensation received from such Third
Party Marketer pursuant to clause (a) is recouped or recovered by, or repaid to,
such Third Party, the amount of such recoupment, recovery or repayment. Any
compensation received in any form other than cash shall be valued in good faith
by the parties.

           1.12 "* * *" shall mean * * * in an injectable finished product
formulation which is or may become the subject of an ANDA.

           1.13 "PATENT RIGHTS" shall mean (a) all patent applications
heretofore or hereafter filed or having legal force in any country owned by or
licensed to Aesgen or to which Aesgen otherwise acquires rights, which claim the
Products, or the process of manufacture or use of the Products, together with
any and all patents that have issued or in the future issue therefrom, including
utility model and design patents and certificates of invention; and (b) all
divisionals, continuations, continuations-in-part, reissues, renewals,
extensions or additions to any such patents and patent applications; all to the
extent and only to the extent that Aesgen now has or hereafter will have the
right to grant licenses, immunities or other rights thereunder.

           1.14 "PERSON" shall mean an individual, corporation, partnership,
limited liability company, trust, business trust, association, joint stock
company, joint venture, pool, syndicate, sole proprietorship, unincorporated
organization, governmental authority or any other form of entity specifically
listed herein.

           ***  - Confidential treatment requested.

                                    -4-

<PAGE>

           1.15 "PRODUCT", individually, shall mean any of the pharmaceutical
products set forth on EXHIBIT A attached hereto.

           1.16 "PRODUCTS", collectively, shall mean the pharmaceutical products
set forth on EXHIBIT A attached hereto.

           1.17 "SPECIFICATIONS" shall mean the specifications for each of the
Products set forth in the ANDA for such Product.

           1.18 "THIRD PARTY" shall mean any Person other than Sicor, Aesgen and
their respective Affiliates.

           1.19 "THIRD PARTY MANUFACTURER" shall mean any Third Party who
manufactures * * * for supply to Sicor under this Agreement.

           1.20 "THIRD PARTY MARKETER" shall mean any Third Party appointed by
Sicor to market, promote and sell Products to customers; PROVIDED, HOWEVER, that
this shall exclude any Third Party set forth on the list attached hereto as
EXHIBIT B or any other Third Party that shall provide standard distribution or
wholesale services with only incidental promotional activities pursuant to its
standard contracts with manufacturers for the distribution and sale of products.

                                    ARTICLE 2

                         REPRESENTATIONS AND WARRANTIES

           2.1 REPRESENTATIONS BY EACH PARTY. Each party hereby represents and
warrants to the other party, upon the execution of this Agreement, as follows:

                      2.1.1 CORPORATE EXISTENCE AND POWER. Such party (a) is a
corporation duly organized, validly existing and in good standing under the laws
of the jurisdiction in which it is incorporated; (b) has the corporate power and
authority and the legal right to own and operate its property and assets, to
lease the property and assets it operates under lease, and to carry on its
business as it is now being conducted and (c) is in compliance with all
requirements of applicable law, except to the extent that any noncompliance
would not have a material adverse effect on the properties, business, financial
or other condition of such party and would not materially adversely affect such
party's ability to perform its obligations under this Agreement.

                      2.1.2 AUTHORIZATION AND ENFORCEMENT OF OBLIGATIONS. Such
party (a) has the corporate power and authority and the legal right to enter
into this Agreement and to perform its obligations hereunder and (b) has taken
all necessary corporate action on its part to authorize the execution and
delivery of this Agreement and the performance of its obligations hereunder. The
Agreement has been duly executed and delivered on behalf of such party, and
constitutes a legal,

           ***  - Confidential treatment requested.

                                    -5-

<PAGE>

valid, binding obligation, enforceable against such party in accordance with its
terms.

                      2.1.3 CONSENTS. All necessary consents, approvals and
authorizations of all governmental authorities and other Persons required to be
obtained by such party in connection with this Agreement have been obtained.

                      2.1.4 NO CONFLICTS. The execution and delivery of this
Agreement and the performance of such party's obligations hereunder (a) do not
conflict with or violate any requirement of applicable laws or regulations, and
(b) do not conflict with, or constitute a default under, any contractual
obligation of such party.

                                    ARTICLE 3

                                 LICENSE GRANTS

           3.1 TECHNOLOGY LICENSE. Subject to the terms and conditions of this
Agreement, during the term of this Agreement, Aesgen hereby grants to Sicor and
its Affiliates an exclusive worldwide license (exclusive even as to Aesgen),
with the right to sublicense solely as necessary to appoint Third Party
Marketers, under Aesgen and its Affiliates' rights in (i) present and future
ANDAs for * * *, and (ii) the Patent Rights and Know How to make, use, sell,
offer for sale, import and distribute * * * made by the methods disclosed in
such ANDAs.

           3.2 MANUFACTURING LICENSE. Aesgen hereby grants to Sicor and its
Affiliates an exclusive worldwide license (exclusive even as to Aesgen) under
the Patent Rights and the Know How to develop and make the Products.

           3.3 THIRD PARTY MARKETERS. Sicor shall not appoint a Third Party
Marketer of the Products without the prior written consent of Aesgen, which
consent shall not be unreasonably withheld or delayed, PROVIDED, HOWEVER, that
Aesgen may not refuse its consent to any Third Party Marketer which, pursuant to
its agreement with Sicor, (a) undertakes to market and sell Products with at
least the same degree of diligence as such Third Party Marketer's other products
and refrain from using any Products as "loss leaders"; (b) has at least 5 years
of experience in the sale and distribution of pharmaceutical products; and (c)
has terms relating to the definition of "net sales" which are consistent with
the definition of such term in this Agreement and require such Third Party
Marketer to provide the reconciliation report provided in Section 6.3. In
connection with the foregoing, Sicor shall provide Aesgen with a copy of any
term sheets or similar proposals relating to any proposed Third Party Marketer,
and permit Aesgen to review and comment on such proposals. Aesgen's comments
will be given due consideration by Sicor in negotiating the terms of any
arrangement with a potential Third Party Marketer.

           ***  - Confidential treatment requested.

                                    -6-

<PAGE>

                                    ARTICLE 4

                        DEVELOPMENT AND OTHER OBLIGATIONS

           4.1 DEVELOPMENT ACTIVITIES. Sicor and Aesgen shall use commercially
reasonable efforts to develop, conduct all testing and apply for and obtain
regulatory approval to market the Products, in accordance with the development
responsibilities of the parties set forth in Section 4.1.1 and in accordance
with the schedule attached hereto as EXHIBIT C.

                      4.1.1 DEVELOPMENT RESPONSIBILITIES.

                                 (a) LYOPHILIZED PRODUCTS. Sicor shall use
reasonable commercial efforts to conduct or cause the design, development and
manufacturing scale-up of the Lyophilized Products and the generation of all
data and associated reports for all stability studies in support of the ANDAs
for the Products and as required to amend or supplement Aesgen's ANDA for the *
* * Lyophilized Product to (i) qualify Sicor's Irvine, California facility as a
manufacturing site of the * * * Lyophilized Product and (ii) add the * * *
Lyophilized Product.

                                 (b) LIQUID PRODUCTS. Sicor shall use reasonable
commercial efforts to conduct or cause the design, development and manufacturing
scale-up of the Liquid Products and the generation of all data and associated
reports for all stability studies in support of the ANDAs for each of such
Liquid Products.

                                 (c) REGULATORY APPROVAL Aesgen shall be
responsible for obtaining all necessary regulatory approvals for the sale of the
Products and for maintaining the ANDAs for each of the Products, except as
otherwise specifically provided. The parties shall discuss and reach an
agreement as to whose name shall be used on any future ANDA filings; PROVIDED,
HOWEVER, that Sicor may elect, in its sole discretion, to file and maintain the
ANDA, at its expense and in its name, for the Liquid Products.

                      4.1.2 TECHNOLOGY TRANSFER. Promptly after the execution of
this Agreement, Aesgen shall provide Sicor with the Know-How and any other
technology or information in its possession relating to the manufacture of * *
*, consisting of the technical sections of Aesgen's ANDA for * * * and the
information set forth in EXHIBIT D attached hereto, together with such other
information as Sicor may reasonably request.

                      4.1.3 COOPERATION. Aesgen shall reasonably cooperate, or
cause its contractors to cooperate, with Sicor in order to address technical and
regulatory issues related to the manufacture of * * *. Aesgen shall make
available to Sicor on a regular basis and upon request information regarding the
status of the ANDAs for the Products, and shall promptly furnish Sicor with
copies of all communications between Aesgen and applicable regulatory
authorities (including the FDA) concerning the Products. Aesgen shall make its
employees and agents reasonably available to Sicor in connection with the
cooperation and information sharing provided for herein. Each party shall bear
its own costs in connection with such cooperation.

           ***  - Confidential treatment requested.

                                    -7-

<PAGE>

                      4.1.4 PROCESS VALIDATION. Sicor shall use commercially
reasonable efforts to validate, at its cost, all processes, equipment,
utilities, facilities and computers utilized in the manufacture, packaging,
storage, testing and release of Products for regulatory submissions and
commercial sale in conformance with all current FDA and other applicable
regulatory authority guidelines and regulations. Sicor shall be responsible for
and shall ensure that all validated systems are maintained according to FDA
guidelines and that all required periodic revalidations are performed according
to FDA guidelines.

           4.2 FUNDING. Each party shall be responsible for paying all costs for
the performance of its obligations under this Agreement, except as otherwise
specifically provided in this Agreement.

           4.3 CHANGES TO SPECIFICATIONS. In the event that any change to the
Specifications for a Product is required by any governmental authority, Aesgen
shall deliver written notice to Sicor specifying such change required by such
governmental authority. Sicor shall notify Aesgen in writing in the event that
it cannot, in good faith, agree to such change. If Sicor determines that such
change in the Specifications required by such governmental authority cannot be
so agreed to, then Aesgen and Sicor shall negotiate, in good faith, an amendment
to the Agreement deleting the Product to which the Specification sought to be
changed is applicable and altering or adding such other terms as may be just and
suitable in the circumstances.

           4.4        DEVELOPMENT FUNDING.

                      4.4.1 MILESTONE PAYMENTS. In consideration for Aesgen's
participation in the development pursuant to Section 4.1, Sicor shall pay Aesgen
the following nonrefundable amounts upon achievement of the applicable
milestones set forth below.

                                 (a) MILESTONE 1. Upon the execution and
delivery by Aesgen of this Agreement, Sicor shall pay Aesgen * * *.

                                 (b) MILESTONE 2. Sicor shall pay Aesgen * * *,
upon the earlier of (i) the successful transfer of technical information,
methods and Know How set forth in EXHIBIT D from Aesgen to Sicor pursuant to
Section 4.1.2 above and the successful manufacture of the required accelerated
stability pilots for the Lyophilized Products as evidenced by in-specification
release testing of pilot samples; or (ii) July 3, 2000. In the event that a
Lyophilized Product fails to meet the specifications for chemical stability at
the three (3) month stability time point, Sicor may take a credit against the
percentage payments payable to Aesgen pursuant to Article 6 below of * * *.

                                 (c) MILESTONE 3. Sicor shall pay Aesgen * * *
upon the earlier of (i) FDA acceptance of the filing of the ANDA supplement
designating Sicor's Irvine, California facility as an alternative manufacturing
site for the Lyophilized Products; or (ii) January 2, 2001.

           *** - Confidential treatment requested.

                                    -8-

<PAGE>

                      4.4.2 REGULATORY COSTS. Aesgen shall pay all costs of
obtaining regulatory approval to market all of the Products; PROVIDED, HOWEVER,
that Sicor shall be responsible for funding the costs of obtaining regulatory
approval for any Product for which Sicor elects to maintain an ANDA filing in
Sicor's name, excluding any costs relating to the prosecution or defense of any
patent claims related to such filing.

                                    ARTICLE 5

                             REGULATORY SUBMISSIONS

           5.1 REGULATORY APPROVAL. Except as set forth in Section 4.1.1, Aesgen
shall use commercially reasonable efforts to obtain ANDA approval for the
Products. Following the approval of an ANDA filed by Aesgen, Aesgen shall,
during the term of this Agreement, maintain in full force and effect, and comply
with all conditions attached to, each such ANDA.

           5.2 REGULATORY CONTACTS. The party filing an ANDA with respect to any
Product shall be responsible for all regulatory contacts and filings with the
FDA with respect to such Product. Each party agrees to consult with the other
party prior to any material meetings or filings with the FDA with respect to any
of the Products after ANDA approval. Both parties shall have the right to attend
any material meetings with the FDA with respect to the Products after ANDA
approval. Each party shall provide the other party in a timely fashion with
copies of all material correspondence with the FDA that relates to any of the
Products after ANDA approval.

           5.3 ADVERSE EXPERIENCE REPORTING. Sicor and Aesgen shall report to
the other any information of which they have knowledge concerning any adverse
drug experience in connection with the use of the Products, including the
incidence or severity thereof, associated with non-clinical toxicity studies,
clinical uses, studies, investigations or tests, whether or not determined to be
attributable to any of the Products. Reports of routine adverse drug experiences
of the type defined in Section 214.80 of Title 21 of the United States Code of
Federal Regulations shall be exchanged by each party on a quarterly basis.
Reports of serious adverse drug experiences of the type defined in Sections
312.32 and 314.80 of Title 21 of the United States Code of Federal Regulations
shall be made available to the other party within five (5) days after a party
becomes aware of such adverse drug experience. Upon receipt of any such
information concerning any serious adverse drug experience by either Sicor or
Aesgen, the parties shall promptly consult each other and use their best efforts
to arrive at a mutually acceptable procedure for taking such possible actions as
appropriate or required under the circumstances; provided, however, that nothing
contained herein shall be construed as restricting the right or duty of either
party to make a required report or submission to the FDA or take any other
action that it deems to be appropriate or required by applicable law or
regulation. In any event, the responsibility of making any reports of adverse
drug experience or other required reports to the FDA shall be upon the holder of
the product registration for the applicable Product.

           5.4       RECALL ACTION.

                                    -9-

<PAGE>

                      5.4.1 In the event Sicor is required or voluntarily
decides to initiate a recall, withdrawal, or field correction of any Product,
Sicor shall notify Aesgen and provide a copy of its proposal, including the
recall letter, for review prior to initiation of such action. In conjunction
with such recall, Aesgen shall assist in the investigation to determine the
cause and extent of the problem.

                      5.4.2 In the event that Aesgen independently believes that
a recall, withdrawal, or field correction of any Product may be necessary or
appropriate, Aesgen shall notify Sicor of Aesgen's belief, and the parties
shall fully cooperate with each other concerning the necessity and nature of
such action.

                      5.4.3 All coordination of any recall or field correction
activities involving Products shall he handled by Sicor whether or not such
action was initially requested by Aesgen.

           5.5 EXPENSES. In the event that any Product is recalled as a result
of the negligent or intentionally wrongful act of Sicor or its representatives,
then Sicor shall bear all of the costs and expenses of such recall, including
expenses related to communications and meetings with all required regulatory
agencies, expenses of replacement stock, the cost of notifying customers and
costs associated with shipment of recalled Product from customers and shipment
of an equal amount of replacement Product to those same customers. In the event
that any Product is recalled as a result of the negligent or intentionally
wrongful act of Aesgen or its representatives, then Aesgen shall bear all of the
costs and expenses of such recall, including expenses related to communications
and meetings with all required regulatory agencies, expenses of replacement
stock, the cost of notifying customers and costs associated with shipment of
recalled Product from customers and shipment of an equal amount of replacement
Product to those same customers. To the extent that the reason for any recall of
Products hereunder is in part the responsibility of Aesgen and in part the
responsibility of Sicor or is not due to the fault of either party, then the
expenses shall be allocated in an equitable manner between the parties.

           5.6 RECALL RECORDS. Sicor shall maintain complete and accurate recall
records for such periods as may be required by applicable law, but in no event
less than three (3) years, of all the Products sold by it.

           5.7 DEBARMENT. Each of Sicor and Aesgen represent that it is not
debarred under the Generic Drug Enforcement Act of 1992 and that it does not
employ or use the services of any individual who is debarred or has engaged in
activity that could lead to debarment.

                                    ARTICLE 6
                                    PAYMENTS

           6.1 SICOR PERCENTAGE PAYMENT. During the term of this Agreement,
Sicor shall pay to Aesgen * * * of the Gross Profit on Products sold by Sicor or
its Affiliates (exclusive of sales to

           ***  - Confidential treatment requested.

                                     -10-

<PAGE>

any Third Party Marketers) each calendar quarter. Such payments shall be made
not more than thirty (30) days following the end of such quarter. A statement
showing the Net Sales calculation of the payment set forth herein for the
applicable quarter shall accompany each payment.

           6.2 THIRD PARTY MARKETER PERCENTAGE PAYMENT. Sicor shall pay to
Aesgen * * * of the Gross Profit on Products sold by Sicor to any Third Party
Marketer. Such payments shall be made not more than ten (10) business days
following the receipt by Sicor of payment from such Third Party Marketer; but in
any event such payment shall be made not later than forty-five (45) days after
the date of Sicor's invoice to such Third Party Marketer for such Products.

           6.3 RECONCILIATION. Sicor shall require any Third Party Marketer to
provide a reconciliation report, and payment of any additional amounts due to
Sicor as shown in such report, within forty-five (45) days after the end of each
calendar quarter to reconcile the amount paid to Sicor at the time of shipment
of Product and any additional amounts which may be due and owing to Sicor under
the terms of the Third Party Marketer's agreement with Sicor. Within ten (10)
business days of receipt by Sicor of any reconciliation payment received from
any Third Party Marketer, Sicor shall pay Aesgen * * * of the Gross Profit of
the sales of Products reflected in such payment. However, in the event that an
overpayment was made to Sicor by any such Third Party Marketer and * * * of such
overpayment was paid by Sicor to Aesgen, Sicor shall, at its option, offset
against payments to Aesgen under this Agreement or invoice the amount of such
overpayment to Aesgen (provided that the amount of such offset or invoice shall
not have the effect of reducing the Gross Profits with respect to the sales of
such Products to less than zero) and Aesgen shall pay to Sicor such amount
within fifteen (15) days of the date of such invoice.

           6.4 AUDIT RIGHT. For a period of three (3) years after Aesgen
receives from Sicor any Gross Profit payments, Sicor shall keep and maintain
books and records in sufficient detail to support calculation of such Gross
Profits (including Net Sales and Manufacturing Costs). During such period of
time, upon thirty (30) days prior written notice to Sicor, Sicor shall permit an
independent certified public accountant appointed by Aesgen and reasonably
acceptable to Sicor, upon reasonable notice and during normal business hours, to
examine all relevant records and all other documents in the possession or
control of Sicor as may be necessary to verify the validity and/or correctness
of Gross Profits actually paid or payable by Sicor pursuant to the terms of this
Agreement. Such accountants shall be required to execute a confidentiality
agreement and shall report to Aesgen only the amount and relevant details of any
discrepancy in the calculations. The results of any such examination shall be
made available to and shall be binding upon both parties. Promptly after such
examination, the appropriate party shall make payment, or issue a credit, to the
other party to eliminate any discrepancy disclosed by such examination. Aesgen
shall bear the full cost of the performance of any such audit unless the results
of such audit indicate that the actual Gross Profits paid were, in the
aggregate, less than 95% of the amount reported or paid to Aesgen, in which
event Sicor shall bear such cost.

           ***  - Confidential treatment requested.

                                    -11-

<PAGE>

           6.5 TAXES. All federal, state, district, local or other governmental
authority income or similar tax measured by income that is imposed on either
party as a result of income generated as a result of the transactions
contemplated under this Agreement, shall be the responsibility of such party.
Any federal, state, district, local or other governmental authority sales or use
tax, excise or similar tax assessed on the sale of Products by Sicor shall be
paid by Sicor.

           6.6 CUSTOMER PRICING. Sicor shall have sole discretion in setting
customer pricing for the Products.

                                    ARTICLE 7

                         CONFIDENTIALITY AND PUBLICATION

           7.1 CONFIDENTIALITY OBLIGATION. During the term of this Agreement,
and for a period of seven (7) years following the expiration or earlier
termination hereof, each party will not disclose to any Third Party absent an
express written agreement permitting such disclosure and will not use for any
purpose other than the purpose of this Agreement, any and all Confidential
Information received from the other party on a confidential basis. Each party
shall use the same degree of care, which shall not be less than a reasonable
degree of care, that it uses to protect its own confidential information to
prevent the unauthorized disclosure of Confidential Information. "Confidential
Information" shall mean any information furnished to it by the other party or
developed by it under or in connection with this Agreement, whether in oral,
written, electronic of the form which is marked or otherwise identified as
"confidential" when disclosed to the other party or given the context the
receiving party should reasonably know to be confidential. The foregoing
confidentiality obligation shall not apply to information which: (i) Aesgen or
Sicor is required to disclose by any governmental body in connection with the
registration and the marketing of the Products, or (ii) at the time of the
disclosure, is in the public domain, or (iii) after disclosure, becomes part of
the public domain through no fault of the receiving party, or (iv) was
previously known to the receiving party from a source other than the disclosing
party and such source was under no obligation to keep such information
confidential or which is received from a third party, provided said party did
not obtain it directly or indirectly from the disclosing party or a party who
was under a duty to keep such information confidential, or (v) becomes known to
the receiving party as a result of its own efforts achieved independently from
the information received under this Agreement.

           7.2 PERMITTED DISCLOSURE. Either party (the "publishing party") may
use or refer to the name of the other party: (i) in connection with the
publishing party's efforts to secure financing at any time during the term of
this Agreement, so long as such statements do not disclose any Confidential
Information of the other party; (ii) in connection with a press release
regarding this Agreement and the relationship of the parties created hereby,
which shall be mutually agreed upon by the parties; or (iii) in statements that
the publishing party reasonably determines to be necessary to comply with
applicable law (including the disclosure requirements of the U.S. Securities and
Exchange Commission, Nasdaq or any other stock exchange on which securities
issued by the publishing party are traded); provided, however, that to the
extent practicable under the circumstances, the publishing party shall provide
the other party with a copy of the proposed

                                    -12-

<PAGE>

text of such statements sufficiently in advance of the scheduled release
thereof to afford such other party a reasonable opportunity to review and
comment upon the proposed text. Except as permitted in this provision,
neither party shall disclose, use or refer to, without the other party's
prior written consent which consent shall not be unreasonably withheld or
delayed, the name or trademarks of such other party in any public statements,
whether oral or written, including shareholder reports, communications with
stock market analysts or other communications with the media, or prospectuses.

           7.3 TERMS OF THIS AGREEMENT. Neither Sicor nor Aesgen shall disclose
any terms or conditions of this Agreement to any Third Party not otherwise
publicly disclosed without the prior written consent of the other party, except
as required by applicable law or to Persons with whom Sicor or Aesgen has
entered into or proposes to enter into a business relationship, provided that
such Persons shall enter into the required confidentiality agreement.
Notwithstanding the foregoing, prior to execution of this Agreement, Sicor and
Aesgen shall agree upon the substance of information that can be used to
describe the terms of this transaction, and Sicor and Aesgen my disclose such
information, as modified by mutual agreement from time to time, without the
other party's consent.

                                    ARTICLE 8

                                  PATENT RIGHTS

           8.1 OWNERSHIP. As between Aesgen and Sicor, Aesgen shall be the
exclusive owner of the all Patent Rights and Know-How, and all other
intellectual property rights relating to the technology transferred to Sicor
pursuant to Section 4.1.2. The entire right and title in all inventions,
discoveries, improvements or other technology directed to the manufacture or use
of a Product, and all processes relating thereto, whether or not patentable, and
any patent applications or patents based thereon, made or conceived during and
as a result of the development program (collectively the "Inventions") (a) by
employees or others acting solely on behalf of Sicor, or its Affiliates shall be
owned solely by Sicor (the "Sicor Inventions"), (b) by employees or others
acting solely on behalf of Aesgen or its Affiliates shall be owned solely by
Aesgen (the "Aesgen Inventions"), and (c) by employees or others acting jointly
on behalf of Sicor and Aesgen, or their respective Affiliates, shall be owned
jointly by Sicor and Aesgen (the "Joint Inventions"). Each party promptly shall
disclose to the other party the making, conception or reduction to practice of
Inventions by employees or others acting on behalf of such party. Sicor and
Aesgen each hereby represents that all employees and other Persons acting on its
behalf in performing its obligations under the Agreement shall be obligated
under a binding written agreement to assign to it, or as it shall direct, all
Inventions made or developed by such employees or other Persons.

           8.2 PROSECUTION, MAINTENANCE AND ENFORCEMENT. Aesgen shall be
responsible for and shall bear all applicable costs associated with the filing,
prosecution and maintenance of the Patent Rights. Aesgen and Sicor shall
promptly notify the other in writing of any alleged or threatened infringement
of Patent Rights of which they become aware. Aesgen shall have the right to
prosecute any infringement described in this Section 8.2. If Aesgen elects not
to proceed

                                    -13-

<PAGE>

with enforcement activity within (i) ninety (90) days following the notice of
alleged infringement or (ii) ten (10) days before the time limit, if any, set
forth in the appropriate laws and regulations for the filing of such actions,
whichever comes first, then Sicor may act in its own name to commence
litigation with respect to the alleged or threatened infringement. In the
event a party brings an infringement action, the other party shall cooperate
fully, including, if required to bring such action, the furnishing of a power
of attorney. Neither party shall have the right to settle any patent
infringement litigation under this Section 8.2 in a manner that diminishes
the rights or interests of the other party without the express written
consent of such other party. The costs of any litigation commenced pursuant
to this Section 8.2, including attorneys' fees and expenses, shall be borne
by the party commencing such litigation, unless the parties agree to a
different cost sharing arrangement in any particular matter. Except as
otherwise agreed to by the parties as part of a cost sharing arrangement, any
recovery realized or liability created as a result of such joint litigation
shall be shared equally by the parties, after deduction of the costs of
litigation incurred by the party commencing such litigation (unless they
agree beforehand to a different sharing of such recovery).

           8.3 THIRD PARTY INFRINGEMENT ACTIONS. If Aesgen or Sicor, any Third
Party Marketer or their respective customers is sued by a Third Party for
infringement of a patent because of the manufacture, use or sale of a Product,
other than due to the manufacture of Bulk Intermediate (which shall be governed
by the terms of that certain supply agreement between Aesgen and Sicor S.p.A.,
as amended (the "Supply Agreement")), each party promptly shall notify the other
party in writing of the institution of such suit. In such event, Aesgen shall
have the right to delay launch of such affected Products or cease the marketing
and sales of such affected Products until the resolution of such matter upon a
reasonable determination by Aesgen that such delay is necessary. Sicor and
Aesgen agree to use their commercially reasonable efforts to mutually settle any
litigation relating to the infringement of any issued patents. Except as
otherwise provided in Article 10 hereof, any recovery realized or liability
created as a result of such joint litigation shall be shared equally by the
parties, after deduction of the costs of litigation incurred by each of the
parties in connection with such litigation (unless they agree beforehand to a
different sharing of such recovery).

           8.4 NO OTHER TECHNOLOGY RIGHTS. Except as otherwise provided in this
Agreement, under no circumstances shall a party, as a result of this Agreement,
obtain any ownership interest or other right in any technology, know-how,
patents, pending patent applications, products, or materials of the other party,
including items owned, controlled or developed by the other, or transferred by
the other to such party at any time pursuant to this Agreement. It is understood
and agreed by the parties that this Agreement does not grant to either party any
license or other right in basic technology of the other party except to the
extent necessary to enable the parties to carry out their part of the
development, manufacture and marketing of the Products.

                                    -14-

<PAGE>

                                    ARTICLE 9

                              TERM AND TERMINATION

           9.1 TERM. Unless terminated earlier, this Agreement shall commence
from the date of this Agreement and continue in full force and effect for an
initial term of five (5) years after the date of this Agreement, as set forth in
the introductory paragraph, or, if the required marketing approval to market any
Product has been received before such time, then the initial term shall be for
seven (7) years after receipt of the approval of the last Product for which such
approval is received. The term of this Agreement shall be automatically renewed
for successive periods of one year each, unless either party notifies the other
not less than six (6) months prior to the end of the initial term or any renewal
term that this Agreement shall terminate at the end of such initial term or
renewal term.

           9.2        TERMINATION FOR OTHER REASONS.

                      9.2.1 Except as otherwise provided in the Section
regarding force majeure, any party may terminate this Agreement:

                                 (a) upon or after the material breach of this
Agreement by the other party if that party has not cured such breach within
sixty (60) days after receipt of written notice thereof by the nonbreaching
party; PROVIDED, HOWEVER, that each party shall have such longer period as
may be needed to cure such breach provided that it has promptly commenced and
continues diligently to pursue such cure;

                                 (b) upon failure by Sicor to successfully
manufacture the required accelerated stability pilots for the Lyophilized
Products by December 31, 2000;

                                 (c) subject to applicable bankruptcy laws, if
the other party voluntarily commences any action or seeks any relief
regarding its liquidation, reorganization, dissolution or similar act or
under any bankruptcy, insolvency or similar law; or

                                 (d) subject to applicable bankruptcy laws, if a
proceeding is commenced or an order, judgment or decree is entered seeking
the liquidation, reorganization, dissolution or similar act or any other
relief under any bankruptcy, insolvency or similar law against the other
party, without its consent, which continues undismissed or unstayed for a
period of sixty (60) days.

                      9.2.2 Sicor may, upon written notice to Aesgen, terminate
this Agreement if as a result of an infringement action described Section
8.3, Aesgen elects to delay launch of such a Product affected by such an
action or cease the sale of a Product affected by such an action until the
resolution of such matter, and such delay or cessation lasts for more than
one (1) year.

           9.3       SURVIVAL.

                                    -15-

<PAGE>

                      9.3.1 Termination of this Agreement for any reason shall
not release either party hereto from any liability which, at the time of such
termination, has already accrued to the other party.

                      9.3.2 In the event this Agreement expires pursuant to
Section 9.1 or is terminated by Sicor pursuant to Sections 9.2.1(a), (c) or
(d), Sicor, its Affiliates and Third Party Marketer shall have the right to
sell or otherwise dispose of the stock of any Products then on hand. Sicor
shall make the percentage payments to Aesgen for the sale of such Products in
accordance with Article 6 above.

                     9.3.3 In the event this Agreement is terminated by Aesgen
pursuant to Section 9.2.1(a), Aesgen shall have the option to purchase the
stock of any Products then on hand from Sicor, its Affiliates and Third Party
Marketers at such Person's costs.

                      9.3.4 Articles 6, 7 and 10 and this Section 9.3 shall
survive the expiration and any termination of this Agreement. Except as
otherwise provided in this Article 9, all rights and obligations of the
parties under this Agreement shall terminate upon the expiration or
termination of this Agreement.

                      9.3.5 In the event that this Agreement is terminated by
Sicor pursuant to Sections 9.2.1(a), (c) or (d) above, (i) the licenses
granted to Sicor herein shall survive such termination, subject to a residual
royalty of * * * being paid to Aesgen on the Net Sales of Products thereafter
and (ii) all ANDAs and other regulatory filings shall be transferred or
assigned to Sicor's name or Sicor shall be given a right of cross-reference,
as Sicor may determine. Such royalty payments shall be made in a manner as
nearly as possible consistent with the provisions of Article 6 providing for
the payment of a percentage of Gross Profits.

                      9.3.6 In the event that this Agreement expires pursuant to
Section 9.1, is terminated by Aesgen pursuant to Section 9.2.1(a), (c) or
(d), or is terminated by either party pursuant to Section 9.2.1(b), or if
terminated by Sicor pursuant to Section 9.2.2, then (i) all licenses granted
to Sicor by Aesgen shall terminate, (ii) all ANDAs and other regulatory
filings shall be transferred or assigned to Aesgen's name or Aesgen shall be
given a right of cross-reference, as Aesgen may determine, and (iii) subject
to Sicor's right to sell stock on hand pursuant to Section 9.3.2, Sicor, its
Affiliates and Third Party Marketers shall cease all manufacturing, sales and
marketing of Products under this Agreement.

                                   ARTICLE 10
                                    INDEMNITY

           10.1 INDEMNIFICATION BY SICOR. Sicor agrees to indemnify, defend and
hold harmless Aesgen, its Affiliates and their respective employees against any
and all third-party claims,

           ***  - Confidential treatment requested.

                                    -16-

<PAGE>

losses, damages and liabilities, including reasonable attorney's fees, incurred
by any of them arising out of any breach of any obligation by Sicor hereunder,
any misrepresentation by Sicor hereunder, any negligent or intentionally
wrongful act or omission by Sicor in connection with the manufacture of Products
hereunder.

           10.2 INDEMNIFICATION BY AESGEN. Aesgen agrees to indemnify, defend
and hold harmless Sicor, its Affiliates, its employees, or any of their
customers against any all third party claims, losses, damages and liabilities,
including reasonable attorney's fees, incurred by any of them arising out of any
claim that any of the Products, or the manufacture or use of any of them in
accordance with any approved indications, infringes one or more claims of a
patent or any trade secret or other intellectual property right, or arising out
of any breach of any obligation by Aesgen hereunder, any misrepresentation by
Aesgen hereunder, any negligent or intentionally wrongful act or omission by
Aesgen in connection with the performance of this Agreement by Aesgen. Aesgen
shall pay all damages and costs awarded by a court of competent jurisdiction,
unappealed and unappealable.

           10.3 PROCEDURE. If Aesgen, its affiliates or their respective
employees or customers, or Sicor, its affiliates or their respective employees
(in each case an "Indemnified Party") receive any written claim which such
Indemnified Party believes is the subject of indemnity hereunder by Sicor or
Aesgen as the case may be (in each case an "Indemnifying Party"), the
Indemnified Party shall, as soon as reasonably practicable after forming such
belief, give notice thereof to the Indemnifying Party; provided, that the
failure to give timely notice to the Indemnifying Party as contemplated hereby
shall not release the Indemnifying Party from any liability to the Indemnified
Party unless the Indemnifying Party demonstrates that the defense of such claim
is prejudiced by such failure. In case any such proceeding shall be brought
against any Indemnified Party and it shall notify the Indemnifying Party of the
commencement thereof, the Indemnifying Party shall be entitled to participate
therein and, to the extent that it shall wish to assume the defense thereof,
with counsel satisfactory to such Indemnified Party and shall pay as incurred
the fees and disbursements of such counsel related to such proceeding. In any
such proceeding, any Indemnified Party shall have the right to retain its own
counsel at its own expense. Notwithstanding the foregoing, the Indemnifying
Party shall pay as incurred (or within 30 days of presentation) the fees and
expenses of the counsel retained by the Indemnified Party in the event (i) the
Indemnifying Party and the Indemnified Party shall have mutually agreed to the
retention of such counsel, (ii) the named parties to any such proceeding
(including any impleaded parties) include both the Indemnifying Party and the
Indemnified Party and representation of both parties by the same counsel would
be inappropriate due to actual or potential differing interests between them or
(iii) the Indemnifying Party shall have failed to assume the defense and employ
counsel acceptable to the Indemnified Party within a reasonable period of time
after notice of commencement of the action. It is understood that the
Indemnifying Party shall not, in connection with any proceeding or related
proceedings in the same jurisdiction, be liable for the reasonable fees and
expenses of more than one separate firm for all such indemnified parties. Such
firm shall be designated in writing by Sicor in the case of parties indemnified
pursuant to Section 10.1 and by Aesgen in the case of parties indemnified
pursuant to Section 10.2. The Indemnifying Party shall not be liable for any
settlement of any proceeding effected without its written consent but if settled
with such consent or if there be a

                                    -17-

<PAGE>

final judgment for the plaintiff, the Indemnifying Party agrees to indemnify
the Indemnified Party from and against any loss or liability by reason of
such settlement or judgment. In addition, the Indemnifying Party will not,
without the prior written consent of the Indemnified Party, settle or
compromise or consent to the entry of any judgment in any pending or
threatened claim, action or proceeding of which indemnification may be sought
hereunder (whether or not any Indemnified Party is an actual or potential
party to such claim, action or proceeding) unless such settlement, compromise
or consent includes an unconditional release of each Indemnified Party from
all liability arising out of such claim, action or proceeding. Any losses,
claims, damages, liabilities or expenses for which an Indemnified Party is
entitled to indemnification under this Article 10 shall be paid by the
Indemnifying Party to the Indemnified Party as such losses, claims, damages,
liabilities or expenses are incurred.

           10.4 INSURANCE. Each party shall carry comprehensive general
liability insurance, including product liability insurance against claims for
bodily injury or property damage in an amount of not less than $3,000,000 per
occurrence and $8,000,000 in the aggregate. Such policy shall be endorsed to
include the following: (a) the policies shall provide for thirty (30) days'
notice to the other party of cancellation or material change in the coverage
before such cancellation or change takes effect; and (b) contractual liability
including this Agreement. Each party shall carry the insurance coverage set
forth herein during the term of this Agreement and for five (5) years following
termination of this Agreement.

                                   ARTICLE 11
                                  MISCELLANEOUS

           11.1 NOTICES. Any consent, notice or report required or permitted to
be given or made under this Agreement by one of the parties to the other shall
be in writing, delivered by any lawful means, addressed to such other party at
its address indicated below, or to such other address as the addressee shall
have last furnished in writing to the addressor and (except as otherwise
provided in this Agreement) shall be effective upon receipt by the addressee.

                                    -18-

<PAGE>

                     If to Sicor:         SICOR Inc.
                                          19 Hughes
                                          Irvine, California 92618
                                          Attention:  PRESIDENT

                     with a copy to:      SICOR Inc.
                                          19 Hughes
                                          Irvine, California 92618
                                          Attention:  SENIOR LEGAL COUNSEL

                     If to Aesgen:        Aesgen, Inc.
                                          2 Research Way
                                          Third Floor East
                                          Princeton, New Jersey 08540
                                          Attention:  President

           11.2 FORCE MAJEURE. Neither party shall be held liable or responsible
to the other party nor be deemed to have defaulted under or breached this
Agreement for failure or delay in fulfilling or performing any term of this
Agreement (except the payment of money due under this Agreement) to the extent,
and for so long as, such failure or delay is caused by or results from causes
beyond the reasonable control of the affected party including fire, floods,
embargoes, war, acts of war (whether war be declared or not), insurrections,
riots, civil commotions, strikes, lockouts or other labor disturbances, acts of
God or acts, omissions or delays in acting by any governmental authority. The
party so affected shall give prompt notice to the other party of such cause, and
shall take whatever steps are necessary to relieve the effect of such cause as
rapidly as reasonably possible.

           11.3 NON-COMPETE. Except pursuant to the terms of this Agreement or
the Supply Agreement, during the term of this Agreement and for one year
thereafter, Sicor shall not make, use, sell, market or distribute anywhere in
the world any products in any form which contain * * * as a bulk ingredient or *
* * as an active ingredient. Except pursuant to the terms of this Agreement or
the Supply Agreement during the term of this Agreement, Aesgen shall not
develop, make, use, sell, market or distribute anywhere in the world any
products in any form which contain * * * as a bulk ingredient or * * * as an
active ingredient.

           11.4 THIRD PARTY PAYMENTS. Sicor shall be entitled to receive fifty
percent (50%) of any compensation received by Aesgen from a Third Party in
consideration of Aesgen's agreement to reduce or stop manufacture and/or sales
of finished dosage forms of Products, unless otherwise agreed to by Aesgen and
Sicor.

           11.5 ASSIGNMENT. Except as expressly provided hereunder, this
Agreement may not be assigned or otherwise transferred, nor may any right or
obligations hereunder be assigned or transferred by either party without the
consent of the other party which may not be unreasonably

           ***  - Confidential treatment requested.

                                    -19-

<PAGE>

withheld or delayed; provided, however, that either may, without such consent,
assign this Agreement and its rights and obligations hereunder in connection
with the transfer or sale of all or substantially all of its business, or in the
event of its merger or consolidation or change in control or similar
transaction. Any permitted assignee shall assume all obligations of its assignor
under this Agreement.

           11.6 SEVERABILITY. Each party hereby acknowledges that it does not
intend to violate any public policy, statutory or common laws, rules,
regulations, treaty or decision of any government agency or executive body
thereof of any country or community or association of countries. Should one or
more provisions of this Agreement be or become invalid, the parties shall
substitute, by mutual consent, valid provisions for such invalid provisions
which valid provisions in their economic effect are sufficiently similar to the
invalid provisions that it can be reasonably assumed that the parties would have
entered into this Agreement with such provisions. In case such provisions cannot
be agreed upon, the invalidity of one or several provisions of this Agreement
shall not affect the validity of this Agreement as a whole, unless the invalid
provisions are of such essential importance to this Agreement that it is to be
reasonably assumed that the parties would not have entered into this Agreement
without the invalid provisions.

           11.7 U.S. EXPORT LAWS AND REGULATIONS. Each party hereby acknowledges
that the marketing rights and information disclosure requirements of this
Agreement are subject to the laws and regulations of the United States relating
to the export of products and technical information. Without limitation, each
party shall comply with all such laws and regulations.

           11.8 ENTIRE AGREEMENT. The Agreement contains the entire
understanding of the parties with respect to the subject matter hereof. All
express or implied agreements and understandings, either oral or written,
heretofore made are expressly superseded by this Agreement. The Agreement may be
amended, or any term hereof modified, only by a written instrument duly executed
by both parties.

           11.9 HEADINGS. The captions to the several Articles and Sections
hereof are not a part of this Agreement, but are merely guides or labels to
assist in locating and reading the several Articles and Sections hereof.

           11.10 INDEPENDENT CONTRACTORS. It is expressly agreed that Sicor and
Aesgen shall be independent contractors and that the relationship between the
two parties shall not constitute a partnership, joint venture or agency. Neither
Sicor nor Aesgen shall have the authority to make any statements,
representations or commitments of any kind, or to take any action, which shall
be binding on the other, without the prior consent of the party to be bound so.

           11.11 WAIVER. The waiver by either party of any right hereunder or
the failure to perform or of a breach by the other party shall not be deemed a
waiver of any other right hereunder or of any other breach or failure by said
other party whether of a similar nature or otherwise.

11.12      ARBITRATION.

                                    -20-

<PAGE>

                      11.12.1 COMMERCIAL ARBITRATION. Except for the right of
either party to apply to a court of competent jurisdiction for a temporary
restraining order or preliminary injunction to preserve the status quo or
prevent irreparable harm pending the selection and confirmation of an
arbitrator, any dispute arising under this Agreement shall be resolved
through mediation and arbitration. The parties agree to first try to resolve
the dispute informally with the help of a mutually agreed upon mediator. If
the parties cannot agree on a mediator or fail to arrive at a mutually
satisfactory solution through mediation within ten (10) days following the
commencement of such mediation, the parties agree to submit their dispute to
binding arbitration in accordance with the Commercial Arbitration Rules of
the American Arbitration Association. The arbitration shall take place in
Chicago, Illinois.

                      11.12.2 SELECTION OF ARBITRATORS. The arbitration shall be
conducted by one impartial arbitrator chosen by mutual agreement of the
parties or if the parties are unable to agree on a single arbitrator within
ten (10) days of first demand for arbitration, the parties agree to allow the
American Arbitration Association ("AAA") to chose an impartial arbitrator for
the parties. The arbitrator shall be selected from a panel provided by the
American Arbitration Association. The chair shall be an attorney at law, and
the arbitrator shall have a background or training either in chemistry, or
the development and marketing of pharmaceutical products.

                      11.12.3 DISCOVERY AND ARBITRATION PROCEDURES. Upon request
of a party, the arbitrator shall have the authority to permit discovery to
the extent such arbitrator deems appropriate. A court reporter shall record
the arbitration hearing and the reporter's transcript shall be the official
transcript of the proceeding. The arbitrator shall have no power to add or
detract from the agreements of the parties and may not make any ruling or
award that does not conform to the terms and conditions of this Agreement.
The arbitrator shall have no authority to award punitive damages or any other
damages not measured by the prevailing party's actual damages. The arbitrator
shall specify the basis for any damage award and the types of damages
awarded. The decision of the arbitrator shall be final and binding on the
parties and may be entered and enforced in any court of competent
jurisdiction by either party.

                      11.12.4 COSTS AND ATTORNEY'S FEES. The prevailing party in
the arbitration proceedings shall be awarded reasonable attorney fees, expert
witness costs and expenses and all other costs and expenses incurred in
connection with the proceedings, unless the arbitrator shall for good cause
determine otherwise.

                                    -21-

<PAGE>

           11.13 COUNTERPARTS. The Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

           IN WITNESS WHEREOF, the parties have executed this Agreement as of
the date first set forth above.

           SICOR INC.

         By   /s/ Frank C. Becker
            ------------------------------
            Title  Chief Operating Officer
                   ------------------------
           AESGEN, INC.

         By   /s/ Paul Mcgarty
            ------------------------------
            Title  President
                   ------------------------

                                    -22-

<PAGE>

                                    EXHIBIT A

           PRODUCTS

1.    * * * for Injection * * * vial - lyophilized presentation

2.    * * * for Injection * * * vial - lyophilized presentation

3.    * * * Injection * * * vial - liquid presentation

4.    * * * Injection * * * vial - liquid presentation

***  - Confidential treatment requested.

<PAGE>

                                    EXHIBIT B

                      LIST OF DISTRIBUTORS AND WHOLESALERS

Allen Dickson, M.D.
American Medical Distributors
Amerisource
Ashi Inc.
Bellco Drug Corporation
Bergen Brunswig
Bindley Western
Borschow Hosp. & Med.
Burlington Drug Company
Capital Wholesale Drug Company
Cardinal Health
Commons Brothers Inc.
D & K Healthcare Resources
D & K Wholesale
Dakota Drug Inc.
Din Drug
Diversified Healthcare Inc.
Drug Guild Distributors Inc.
F. Dorman Company
Great Lakes Wholesale
Gulf Distribution Incorporated
H. D. Smith Wholesale Drug Co.
Health Tech Inc.
James Brudnick
Jewett Drug Co.
King Drug Company of Florence
Kinray Inc.
McKesson Drug
Medsource Corporation
Morris & Dickson Co.
Nationwide Medical/Surgiccal

<PAGE>

Neuman Distributors
Newbro Drug
North Carolina Mutual Whsl. Co.
Northern Drug Company
Owens & Minor-Sunrise
Physicians Formulary Inc.
Rochester Drug Corp Inc.
Smith Drug Company
Springer Wholesale
Tennessee Whsle Drug
Texas Drug Company
V. F. Grace
Valley Drug Company
Value Drug
Walker Drg. Co.
Walsh Lumpkin Wholesale
Albers Inc. or Hosply Assoc.

<PAGE>

                                    EXHIBIT C

                              DEVELOPMENT SCHEDULE

<TABLE>
<S>                                                               <C>
Transfer of Technology from Aesgen to Sicor                       Q2 2000

Development of liquid presentation of * * * by Sicor              Q3-Q4 2000

Pilot manufacture of * * * and * * * lyophilized * * *            Q2-Q3 2000

Pilot Manufacture of liquid * * * and * * *                       Q4 2000-Q1 2000

ANDA filing for * * * and * * * vial lyophilized * * *            Q4 2000

ANDA filing for * * * and * * * vial liquid * * *                 Q2-Q3 2001

***  - Confidential treatment requested.

</TABLE>

<PAGE>

                                    EXHIBIT D

                           INFORMATION TO BE PROVIDED
<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------------------------
                    INFORMATION                              LYOPHILIZED PRODUCT                          LIQUID PRODUCT
                    -----------                              -------------------                          ---------------
                                                                                                          * * * and * * *
                                                  ------------------------------------------------------------------------
                                                      * * *                   * * *
--------------------------------------------------------------------------------------------------------------------------
<S>                                               <C>                        <C>                          <C>
Product Description (Profile)                     Product description        Description to be             Not applicable
                                                  in the ANDA                taken from the current
                                                                             PDR
--------------------------------------------------------------------------------------------------------------------------
Components                                        Section in ANDA            Same as for * * * product     Not applicable

      API source, specifications,
      test methods, MSDS
--------------------------------------------------------------------------------------------------------------------------
      Excipients: source specifications,          Section in ANDA            Same excipients as * * *mg    Not applicable
      test methods, MSDS (if applicable)                                     product
--------------------------------------------------------------------------------------------------------------------------
Composition                                       Section in ANDA            To be taken from the current   Not applicable
                                                                             PDR
--------------------------------------------------------------------------------------------------------------------------
Method of Manufacture                             Section in ANDA            Not applicable                 Not applicable
      Flow Schematic
      Master Production outline
      Master Batch Record
      Reference To Executed Batch Records
--------------------------------------------------------------------------------------------------------------------------
Specifications                                    Section in ANDA            Not applicable                 Not applicable

In process
Finished product

    - including test methods
    - validation reports
--------------------------------------------------------------------------------------------------------------------------

</TABLE>

*** - Confidential treatment requested.

<PAGE>

                             EXHIBIT D - (continued)

                           INFORMATION TO BE PROVIDED

<TABLE>
<CAPTION>

--------------------------------------------------------------------------------------------------------------------------
                    INFORMATION                    LYOPHILIZED PRODUCT                            LIQUID PRODUCT
                    -----------                    -------------------                            ---------------
                                                                                                      * * * and * * *
--------------------------------------------------------------------------------------------------------------------------
                                                   * * *                            * * *
--------------------------------------------------------------------------------------------------------------------------
<S>                                   <C>                                     <C>                 <C>

Stability                             Stability reports for (a)              Not applicable       Not applicable
      Introduction - Including        innovator product, (b) ANDA
      innovator product               product and (c) a comparison of
      (where applicable)              the innovator product against the
                                      ANDA product stability reports
--------------------------------------------------------------------------------------------------------------------------
      Data to date - Including        Data contained in the ANDA,            Not applicable       Not applicable
      innovator product -             ongoing stability studies
      (where applicable)
--------------------------------------------------------------------------------------------------------------------------
Pre-formulation study(ies)            Development report in ANDA             Preliminary          Not applicable
Effect of                                                                    reports
         - O2
         - light
         - heat
         - moisture
         - metals
--------------------------------------------------------------------------------------------------------------------------
Effect of transient contact           Compatibility Study Reports            Not applicable       Not applicable
components on the Product
   - soft parts ( tubing, filters,
     seals, etc.)
   - hard parts (glass, stainless
     steel, compounding and filling
     equipment)
--------------------------------------------------------------------------------------------------------------------------
Container/Closure Compatibility       Information in ANDA                    Not applicable       Not applicable
--------------------------------------------------------------------------------------------------------------------------
Container/Closure Integrity           Information in ANDA                    Not applicable       Not applicable
--------------------------------------------------------------------------------------------------------------------------
</TABLE>

***  - Confidential treatment requested.

<PAGE>

                                                       EXHIBIT D - (continued)

                                                     INFORMATION TO BE PROVIDED
<TABLE>
<CAPTION>

--------------------------------------------------------------------------------------------------------------------------
                    INFORMATION                           LYOPHILIZED PRODUCT                       LIQUID PRODUCT
                    -----------                           -------------------                       ---------------
                                                                                                    * * * and * * *
--------------------------------------------------------------------------------------------------------------------------
                                                * * *                             * * *
--------------------------------------------------------------------------------------------------------------------------
<S>                                             <C>                               <C>                <C>
Mixing Studies                                  Evaluation of solubilized and     Not applicable     Not applicable
-   mixing speed                                homogenized Product
-   mixing time
-   mixing temperature
--------------------------------------------------------------------------------------------------------------------------
Filter compatibility                             Information in ANDA              Not applicable     Not applicable
--------------------------------------------------------------------------------------------------------------------------

Filter acceptability                             Information in ANDA              Not applicable     Not applicable
--------------------------------------------------------------------------------------------------------------------------
Lyophilization cycle development                 Description in ANDA              Not applicable     Not applicable
(where applicable)
--------------------------------------------------------------------------------------------------------------------------
Antimicrobial preservative efficacy              Not applicable                   Not applicable     Not applicable
(where applicable)
--------------------------------------------------------------------------------------------------------------------------
Admixture studies                                Not applicable                   Not applicable     Not applicable
(where applicable)
--------------------------------------------------------------------------------------------------------------------------
Reconstitution studies                           Information in ANDA              Not applicable     Not applicable
(where applicable)
--------------------------------------------------------------------------------------------------------------------------
Terminal sterilization                           Not applicable                   Not applicable     Not applicable
--------------------------------------------------------------------------------------------------------------------------

</TABLE>

***  - Confidential treatment requested.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}]]